Vishnu Kumarasamy

984 total citations
22 papers, 621 citations indexed

About

Vishnu Kumarasamy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Vishnu Kumarasamy has authored 22 papers receiving a total of 621 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Vishnu Kumarasamy's work include Advanced Breast Cancer Therapies (11 papers), Cancer-related Molecular Pathways (10 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Vishnu Kumarasamy is often cited by papers focused on Advanced Breast Cancer Therapies (11 papers), Cancer-related Molecular Pathways (10 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Vishnu Kumarasamy collaborates with scholars based in United States, China and Poland. Vishnu Kumarasamy's co-authors include Erik S. Knudsen, Agnieszka K. Witkiewicz, Ram Nambiar, Paris Vail, Seth M. Rubin, Daekyu Sun, Sarvind Tripathi, Keelan Z. Guiley, Kevin Lou and Krister J. Barkovich and has published in prestigious journals such as Science, Nature Communications and Cancer Research.

In The Last Decade

Vishnu Kumarasamy

21 papers receiving 617 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vishnu Kumarasamy United States 14 360 271 258 103 68 22 621
Vicky Pui‐Chi Tin Hong Kong 9 479 1.3× 459 1.7× 220 0.9× 219 2.1× 24 0.4× 11 787
Ilenia Segatto Italy 14 251 0.7× 290 1.1× 99 0.4× 198 1.9× 29 0.4× 23 536
Stina Mui Singel United States 11 297 0.8× 336 1.2× 197 0.8× 138 1.3× 66 1.0× 26 599
Anchit Khanna Australia 10 298 0.8× 512 1.9× 112 0.4× 92 0.9× 21 0.3× 16 691
Victor Olivas United States 13 251 0.7× 451 1.7× 244 0.9× 166 1.6× 23 0.3× 19 712
Jonathan T. Lei United States 11 175 0.5× 263 1.0× 207 0.8× 130 1.3× 20 0.3× 30 585
Un-Jung Yun South Korea 6 202 0.6× 289 1.1× 115 0.4× 170 1.7× 17 0.3× 10 511
Ka Tat Siu United States 10 186 0.5× 335 1.2× 82 0.3× 105 1.0× 32 0.5× 15 500
Caterina Aversa Italy 12 285 0.8× 210 0.8× 222 0.9× 108 1.0× 24 0.4× 32 553

Countries citing papers authored by Vishnu Kumarasamy

Since Specialization
Citations

This map shows the geographic impact of Vishnu Kumarasamy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vishnu Kumarasamy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vishnu Kumarasamy more than expected).

Fields of papers citing papers by Vishnu Kumarasamy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vishnu Kumarasamy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vishnu Kumarasamy. The network helps show where Vishnu Kumarasamy may publish in the future.

Co-authorship network of co-authors of Vishnu Kumarasamy

This figure shows the co-authorship network connecting the top 25 collaborators of Vishnu Kumarasamy. A scholar is included among the top collaborators of Vishnu Kumarasamy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vishnu Kumarasamy. Vishnu Kumarasamy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kumarasamy, Vishnu, et al.. (2025). Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222. Cancer Research. 85(7). 1310–1326. 6 indexed citations
2.
Humphrey, K., Eduardo Cortes Gomez, Vishnu Kumarasamy, et al.. (2025). Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma. Molecular Cancer. 24(1). 208–208.
3.
Kumarasamy, Vishnu, Michelle Roti, John Bisi, et al.. (2025). Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle. Nature Communications. 16(1). 1476–1476. 8 indexed citations
4.
Witkiewicz, Agnieszka K., et al.. (2025). RB loss sensitizes triple-negative breast cancer to apoptosis induced by cellular stress. Cell Death Discovery. 11(1). 543–543. 1 indexed citations
5.
Kumarasamy, Vishnu, Costakis Frangou, Prasenjit Dey, et al.. (2024). The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer. Cancer Research. 84(7). 1115–1132. 19 indexed citations
6.
Alqahtani, Tariq, Vishnu Kumarasamy, Sahar S. Alghamdi, et al.. (2023). Adefovir Dipivoxil as a Therapeutic Candidate for Medullary Thyroid Carcinoma: Targeting RET and STAT3 Proto-Oncogenes. Cancers. 15(7). 2163–2163. 3 indexed citations
7.
8.
Kumarasamy, Vishnu, Baishan Jiang, Seth M. Rubin, et al.. (2023). PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies. British Journal of Cancer. 129(8). 1238–1250. 11 indexed citations
9.
Kumarasamy, Vishnu, et al.. (2022). RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models. Oncogene. 41(27). 3524–3538. 14 indexed citations
10.
Witkiewicz, Agnieszka K., Vishnu Kumarasamy, Ioannis Sanidas, & Erik S. Knudsen. (2022). Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy. Trends in cancer. 8(9). 711–725. 30 indexed citations
11.
Knudsen, Erik S., Vishnu Kumarasamy, Sejin Chung, et al.. (2020). Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. Gut. 70(1). 127–138. 59 indexed citations
12.
Kumarasamy, Vishnu, Paris Vail, Ram Nambiar, Agnieszka K. Witkiewicz, & Erik S. Knudsen. (2020). Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition. Cancer Research. 81(5). 1347–1360. 42 indexed citations
13.
Roberts, Patrick J., Vishnu Kumarasamy, Agnieszka K. Witkiewicz, & Erik S. Knudsen. (2020). Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows. Molecular Cancer Therapeutics. 19(8). 1575–1588. 44 indexed citations
14.
Guiley, Keelan Z., Kevin Lou, Krister J. Barkovich, et al.. (2019). p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science. 366(6471). 154 indexed citations
15.
16.
Knudsen, Erik S., Vishnu Kumarasamy, Jared Sivinski, et al.. (2019). Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. Oncogene. 38(18). 3355–3370. 46 indexed citations
17.
Kumarasamy, Vishnu & Daekyu Sun. (2017). Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative. International Journal of Oncology. 51(1). 145–157. 13 indexed citations
18.
19.
Kumarasamy, Vishnu, et al.. (2015). Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine. BMC Cancer. 15(1). 599–599. 29 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vicky Pui‐Chi Tin Breakdown of academic impact, for papers by Ilenia Segatto Breakdown of academic impact, for papers by Stina Mui Singel Breakdown of academic impact, for papers by Anchit Khanna Breakdown of academic impact, for papers by Victor Olivas Breakdown of academic impact, for papers by Jonathan T. Lei Breakdown of academic impact, for papers by Un-Jung Yun Breakdown of academic impact, for papers by Ka Tat Siu Breakdown of academic impact, for papers by Caterina Aversa
Rankless by CCL
2026